CD8A and neoplasm: The aforementioned research also discovered that the USP8 inhibitor (DUB-IN-2) in combination with the ferroptosis inducer, SAS, significantly retarded the tumor growth and promoted CD8+ T-cell infiltration in the TME, thereby enhancing the effectiveness of anti-PD-1 immunotherapy in CRC (49).